Cortechs.ai | Dr. James Brewer on NeuroQuant

Dr. James Brewer on NeuroQuant

DrJamesBrewer.jpgDr. Brewer is the Chief Medical Advisor for Cortechs.ai and was the first physician to incorporate NeuroQuant® into clinical practice. He assisted in the design of the NeuroQuant reports and in the studies that led to NeuroQuant’s FDA clearance in 2006.

In 2004, he joined the faculty of the University of California, San Diego, where he has a joint appointment in Radiology and Neurosciences. Dr. Brewer sees patients at the University of California, San Diego and the Veterans Affairs Hospital in La Jolla.

Dr. Brewer’s primary research interest is human memory. He uses functional and structural magnetic resonance imaging (MRI) to study memory processes in volunteers with healthy memory and in patients with memory impairment, such as cases caused by Alzheimer’s disease (AD).

Dr. Brewer received his graduate and medical training at Stanford University and his neurology residency training at Johns Hopkins University.

In the webinar below, Dr. Brewer shares his experience using NeuroQuant, and gives an overview how NeuroQuant can help physicians improve their assessment of neurodegenerative disease, such as Alzheimer’s disease, multiple sclerosis, epilepsy, as well brain trauma and brain development.

More Resources

04/10/2026

OnQ Prostate Vendor Validation: From Research to Clinical Adoption

OnQ Prostate delivers consistent, reliable AI-powered prostate MRI insights across vendors, ensuring confident diagnosis and streamlined clinical workflows.

03/20/2026

Quantitative MRI, the McDonald Criteria, and the Future of Multiple Sclerosis Care

MRI is the foundation for diagnosing and monitoring multiple sclerosis (MS)

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.
Scroll to Top